Marshall Wace, LLP Cure Vac N.V. Transaction History

Marshall Wace, LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.94 - $4.34 $219,000 - $323,286	-74,490 Reduced 83.6%	14,610 $44,000
Q4 2023 Feb 14, 2024	SELL	$3.96 - $6.41 $110,052 - $178,140	-27,791 Reduced 23.78%	89,100 $375,000
Q3 2023 Nov 14, 2023	BUY	$6.5 - $10.77 $232,531 - $385,285	35,774 Added 44.1%	116,891 $798,000
Q2 2023 Aug 14, 2023	SELL	$6.69 - $12.25 $27,054 - $49,539	-4,044 Reduced 4.75%	81,117 $845,000
Q1 2023 May 15, 2023	SELL	$6.38 - $12.5 $3.25 Million - $6.38 Million	-510,101 Reduced 85.69%	85,161 $593,000
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $1.5 Million - $2.22 Million	261,443 Added 78.32%	595,262 $3.59 Million
Q3 2022 Nov 14, 2022	BUY	$7.48 - $15.24 $13,149 - $26,791	1,758 Added 0.53%	333,819 $2.63 Million
Q2 2022 Aug 15, 2022	BUY	$13.18 - $19.41 $2.11 Million - $3.11 Million	160,279 Added 93.3%	332,061 $4.52 Million
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $2.53 Million - $6.06 Million	171,782 New	171,782 $3.37 Million
Q2 2021 Aug 13, 2021	SELL	$56.91 - $127.53 $2.24 Million - $5.03 Million	-39,415 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$79.79 - $126.29 $3.14 Million - $4.98 Million	39,415 New	39,415 $3.61 Million
Q4 2020 Feb 16, 2021	SELL	$46.76 - $136.27 $576,784 - $1.68 Million	-12,335 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$43.8 - $77.2 $540,273 - $952,262	12,335 New	12,335 $574,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $514M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.